{"id":"placebo-for-ag-120","safety":{"commonSideEffects":[{"rate":"null","effect":"Injection site reaction"}]},"_chembl":null,"_dailymed":null,"mechanism":{"_ai_source":"groq-llama-8b","explanation":"As a placebo, AG-120 does not interact with any molecular targets or biological pathways. It is used as a control in clinical trials to compare the efficacy of the active treatment.","oneSentence":"This drug is a placebo, meaning it has no active therapeutic effect.","_ai_confidence":"high"},"_scrapedAt":"2026-03-28T01:27:04.246Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Acute myeloid leukemia"}]},"trialDetails":[{"nctId":"NCT06707493","phase":"PHASE2","title":"Ivosidenib as Post-HSCT Maintenance for AML","status":"RECRUITING","sponsor":"Massachusetts General Hospital","startDate":"2026-01-16","conditions":"IDH1 Mutation, Acute Myeloid Leukemia (AML), Hematopoietic Stem Cell Transplant (HSCT)","enrollment":75},{"nctId":"NCT03173248","phase":"PHASE3","title":"Study of AG-120 (Ivosidenib) vs. Placebo in Combination With Azacitidine in Participants With Previously Untreated Acute Myeloid Leukemia With an IDH1 Mutation","status":"ACTIVE_NOT_RECRUITING","sponsor":"Institut de Recherches Internationales Servier","startDate":"2017-06-26","conditions":"Newly Diagnosed Acute Myeloid Leukemia (AML), Untreated AML, AML Arising From Myelodysplastic Syndrome (MDS)","enrollment":146},{"nctId":"NCT07075016","phase":"PHASE3","title":"Ivosidenib and Azacitidine With or Without Venetoclax in Adult Patients With Newly Diagnosed IDH1-Mutated AML or MDS/AML Considered Ineligible for Intensive Chemotherapy","status":"RECRUITING","sponsor":"Stichting Hemato-Oncologie voor Volwassenen Nederland","startDate":"2025-08-05","conditions":"Acute Myeloid Leukemia","enrollment":227},{"nctId":"NCT03839771","phase":"PHASE3","title":"A Study of Ivosidenib or Enasidenib in Combination With Induction Therapy and Consolidation Therapy, Followed by Maintenance Therapy in Patients With Newly Diagnosed Acute Myeloid Leukemia or Myedysplastic Syndrome EB2, With an IDH1 or IDH2 Mutation, Respectively, Eligible for Intensive Chemotherapy","status":"ACTIVE_NOT_RECRUITING","sponsor":"Stichting Hemato-Oncologie voor Volwassenen Nederland","startDate":"2019-03-01","conditions":"Acute Myeloid Leukemia, Myelodysplastic Syndrome With Excess Blasts-2","enrollment":968},{"nctId":"NCT02989857","phase":"PHASE3","title":"Study of AG-120 in Previously Treated Advanced Cholangiocarcinoma With IDH1 Mutations (ClarIDHy)","status":"COMPLETED","sponsor":"Institut de Recherches Internationales Servier","startDate":"2017-02-20","conditions":"Advanced Cholangiocarcinoma, Metastatic Cholangiocarcinoma","enrollment":187}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":2,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"phase_3","status":"active","brandName":"Placebo for AG-120","genericName":"Placebo for AG-120","companyName":"Stichting Hemato-Oncologie voor Volwassenen Nederland","companyId":"stichting-hemato-oncologie-voor-volwassenen-nederland","modality":"Small molecule","firstApprovalDate":"","aiSummary":"This drug is a placebo, meaning it has no active therapeutic effect. Used for Acute myeloid leukemia.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":1,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}